Are you working on data-sparse or novel targets? Join us June 11th to learn how Avammune progressed from early concepts to ...

The American Diabetes Association's annual congress will feature a superstar lineup, including weight loss giants Eli Lilly ...

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in ...

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data ...

Analysts and investors were unimpressed by Phase 2 data posted in the spring showing that an amylin analog developed by Roche ...

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in ...

In addition to eliciting 17.3 months median overall survival vs. 8.5 months for patients given standard of care treatment in ...

The FDA must provide consistent and predictable regulatory frameworks if the U.S. is to maintain its leadership in gene ...

Drug production is expected to be one of the main drivers of employment growth in U.S. manufacturing through 2034, with the ...

Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous ...

Deal dynamics between Chinese biotechs and global pharma companies are changing fast, with the biotechs seeking higher ...

Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast ...